Smith & Nephew SNATS (SNN) vs TransMedics Group (TMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Smith & Nephew SNATS (SNN) has outperformed TransMedics Group (TMDX) over the past year, losing 25.0% versus a loss of 33.1%. Over five years, TMDX leads with a +197.6% price change compared with -23.8% for SNN. Smith & Nephew SNATS is the larger company by market cap ($11.28 billion vs $2.74 billion), about 4.1 times the size, while TransMedics Group is growing revenue faster (+37.1% vs +6.1%).
On valuation, Smith & Nephew SNATS trades at a lower forward P/E (11.2x vs 35.0x for TransMedics Group). Smith & Nephew SNATS pays a dividend yielding 1.47%, while TransMedics Group does not currently pay one. TransMedics Group converts more of its revenue into profit, with a net margin of 31.4% versus 10.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SNN | TMDX |
|---|---|---|
| Share price | $26.96 | $79.00 |
| Market cap | $11.28B | $2.74B |
| 1-day change | +0.26% | -2.55% |
| YTD return | -17.83% | -35.06% |
| 1-year return | -24.97% | -33.08% |
| 5-year return | -23.82% | +197.55% |
| P/E ratio (TTM) | 18.34 | 20.47 |
| Forward P/E | 11.18 | 35.05 |
| EPS (TTM) | $1.47 | $3.86 |
| Dividend yield | 1.47% | 0.00% |
| Annual dividend | $0.397 | $0.00 |
| Revenue (latest FY) | $6.16B | $605.49M |
| Revenue growth (YoY) | +6.09% | +37.13% |
| Net income (latest FY) | $625.00M | $190.29M |
| Gross margin | 68.01% | 59.92% |
| Operating margin | 12.88% | 17.93% |
| Net margin | 10.14% | 31.43% |
| 52-week high | $37.51 | $156.00 |
| 52-week low | $26.12 | $60.11 |
| Distance from 52-week high | -28.13% | -49.36% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +19.88% | +26.35% |
| Average volume | 1.65M | 820.41K |
| Shares outstanding | 418.52M | 34.68M |
| Employees | 17,000 | 898 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Smith & Nephew SNATS is about 4.1 times larger than TransMedics Group by market value ($11.28B vs $2.74B).
- Smith & Nephew SNATS offers a meaningfully higher dividend yield (1.47% vs 0.00%).
- TransMedics Group is more profitable, keeping 31.4 cents of every revenue dollar as net income versus 10.1 cents for Smith & Nephew SNATS.
- TransMedics Group grew revenue faster in its latest fiscal year (+37.13% vs +6.09%).
About Smith & Nephew SNATS
SNN stock →Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Healthcare · Medical Devices · 17,000 employees
About TransMedics Group
TMDX stock →TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Healthcare · Medical Devices · 898 employees
SNN vs TMDX FAQ
Which is bigger, Smith & Nephew SNATS or TransMedics Group?
Smith & Nephew SNATS (SNN) is larger, with a market capitalization of $11.28B compared with $2.74B for TransMedics Group (TMDX).
Which stock has performed better over the past year, SNN or TMDX?
SNN returned -24.97% over the past 12 months, compared with -33.08% for TMDX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, SNN or TMDX?
SNN has the lower trailing P/E at 18.3, versus 20.5 for TMDX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Smith & Nephew SNATS or TransMedics Group?
Smith & Nephew SNATS pays a dividend yielding 1.47%, while TransMedics Group does not currently pay a regular dividend.
Are Smith & Nephew SNATS and TransMedics Group in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.